Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Abstract

The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression. However, these reports have not penetrated the community, and many patients do not receive appropriate therapy. Additionally, several immune checkpoint inhibitors have recently been approved for treatment of metastatic disease. The approval of immune checkpoint blockade for patients with platinum-resistant or -ineligible metastatic bladder cancer has led to considerations of expanded use for both advanced and, potentially, localized disease. To address these issues and others surrounding the appropriate use of immunotherapy for the treatment of bladder cancer, the Society for Immunotherapy of Cancer (SITC) convened a Task Force of experts, including physicians, patient advocates, and nurses, to address issues related to patient selection, toxicity management, clinical endpoints, as well as the combination and sequencing of therapies. Following the standard approach established by the Society for other cancers, a systematic literature review and analysis of data, combined with consensus voting was used to generate guidelines. Here, we provide a consensus statement for the use of immunotherapy in patients with bladder cancer, with plans to update these recommendations as the field progresses.Electronic supplementary materialThe online version of this article (doi:10.1186/s40425-017-0271-0) contains supplementary material, which is available to authorized users.

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

“…104,105 All of these approvals have been based on category 2 level evidence with the exception of pembrolizumab as a subsequent treatment option, which has category 1 level evidence supporting the approval. 133…”

The Changing Treatment Landscape for Metastatic Urothelial Carcinoma

“…1,2 Analysis of clinical trial data can identify 3 broad populations of patients: (1) those who show response initially and continue to show response (responders), (2) those who never show response (innate resistance), and (3) those who initially show response but eventually develop disease progression (acquired resistance). 3,4 Of course, resistance to specific agents does play a role. "ICIs in bladder cancer have been remarkable in a subset of patients, but there are still concerns about safety," Dr. Flaig noted.…”

Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis

“…Thus, adjuvant intravesical therapy came into being. It consists of bladder infusion chemotherapy and immunotherapy (6). One of the most effective intravesical therapy is bacillus Calmette-Guerin (BCG), which requires special care for its bio toxicity (7).…”